TEL AVIV, Israel, Aug. 13, 2018 /PRNewswire/ -- iCAN:Israel-Cannabis is pleased to announce that it has entered into a Memorandumof Understanding ("MoU") with Yom Chai, Ltd to co-found the development and clinical validation of a range of cannabis based products.
Yom Chai has deep experience in the U.S. retail cannabis market opening and running dispensaries and production
Expanding its work in the industry with iCAN, Yom Chai, in collaboration with leading American and Israeli scientists and medical professionals is initially developing a formulated suppository targeting people suffering from Crohn's Disease and will develop various targeted cannabis formulations including treatment for children and adults with Autism.
iCAN will be supporting Yom Chai by combining its unique access to innovation and technology with unmatched industry insights and international connections. The signing of this MOU provides iCAN with a combination of revenue, equity and future royalties and represents a further achievement of the company's objective be at the center of cannabis innovation.
"We are excited to join the portfolio of companies at iCAN and their global network of innovative companies to assist in the development of world class medical treatments," said Scot Albert, CEO of Yom Chai.
Saul Kaye, CEO of iCAN: Israel-Cannabis said, "Israel boasts the leading clinical researchers in Crohn's Disease and Autism, so it will be possible to leverage the local medical cannabis ecosystem to bring Yom Chai's products to patients as quickly as possible."
About iCAN: Israel-Cannabis
iCAN is a globally recognized Israeli company focused on the medical cannabis industry. iCAN operates across all verticals: consulting, business development, mentoring, investment strategy, network and media, compliance, and regulation, CRO, commercialization, formulation, and international distribution. iCAN produces CannaTech, the global leader in international medical cannabis conferences. For more about iCAN click here.
About Yom Chai
Yom Chai's objective is to conduct scientific trials in Israel utilizing various cannabinoid profiles with the goal of realizing multiple successful discoveries. Yom Chai's goal is to bridge the gap between patients and doctors to bring scientifically proven products to market. For more information on Yom Chai please visit us at www.yomchai.com.
Interested in knowing more or developing your own cannabis product please contact us at endoCRO@israel-cannabis.com
For further information contact Laura Kam at firstname.lastname@example.org +972-54-806-8613.
View original content:http://www.prnewswire.com/news-releases/icanisrael-cannabis-continues-to-accelerate-cannabis-innovation-signs-mou-with-new-israeli-medical-cannabis-company-yom-chai-to-develop-and-clinically-validate-suppository-based-cannabis-treatments-300695938.html
SOURCE iCAN: Israel-Cannabis
Subscribe to our Free Newsletters!
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...View All